Cansino Biologics Inc. is a biopharmaceutical company that develops, manufactures, and commercializes vaccines for the prevention and treatment of infectious diseases. The company's product portfolio includes the Ebola virus disease vaccine Ad5-EBOV, a recombinant tuberculosis vaccine candidate, meningococcal combined vaccines, and a pneumococcal conjugate vaccine. It also developed the adenovirus vector-based COVID-19 vaccines Ad5-nCoV and Ad26-COV2.S. Cansino Biologics operates primarily in the People's Republic of China and has engaged in international collaborations, including a partnership with deepGeneAI to explore personalized mRNA cancer vaccines. The company utilizes adenovirus vector technology platforms to create its vaccine pipeline, which covers multiple infectious diseases such as pneumonia, tuberculosis, and meningitis.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage cansinotech.com
Sector Healthcare IR page cansinotech.com
Tags
vaccines, infectious diseases, adenovirus vector, ebola, tuberculosis, meningitis, pneumonia, mrna cancer vaccines, biopharmaceuticals, Ad5-EBOV, Ad5-nCoV, Ad26-COV2.S, deepGeneAI
Press page cansinotech.com/Newsroom

Metrics

Valuation  
Market cap HK$ 2.91B
Market cap (USD) $ 370.855M
P/E 174.05
PEG —
P/BV 0.93
P/S 2.01
P/OCF -54.81
P/FCF —
Dividend yield —
Turnover / mcap 1.6%
Returns  
ROE 0.57%
ROI 0.45%
ROIC 0.51%
Profit margin 2.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 19.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 1.059B 824.884M 345.182M 1.031B 4.3B 18.544M 0 1.132M
Net profit 27.873M -383.671M -1.967B -964.757M 1.914B -396.638M -156.766M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 46.27 28.48 26.39 57.32 127.64 171.77 59.01 22.7
Price performance 12m 0.66 0.09 -0.57 -0.57 -0.2 1.92 1.52 —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Cansino Biologics Inc. (ticker 6185), listed in Hong Kong.

ETFs Holding Cansino Biologics Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 12,000 $ 35.196K Nov 16, 2026
DFAE 0.00% 62,200 $ 205.043K Nov 12, 2026
DFEM 0.00% 60,200 $ 198.45K Nov 12, 2026
DFAX 0.00% 39,400 $ 129.883K Nov 12, 2026